Thomas F Patterson
Overview
Explore the profile of Thomas F Patterson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
191
Citations
17275
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tisdale-Macioce N, Green J, Perl A, Ashbaugh A, Wiederhold N, Patterson T, et al.
Front Fungal Biol
. 2023 Sep;
2:740845.
PMID: 37744131
species (spp.) are host-obligate fungal parasites that colonize and propagate almost exclusively in the alveolar lumen within the lungs of mammals where they can cause a lethal pneumonia. The emergence...
12.
Smith D, Gold J, Chiller T, Bustamante N, Marinissen M, Rodriquez G, et al.
Clin Infect Dis
. 2023 Sep;
78(6):1554-1558.
PMID: 37739479
Background: Public health officials are responding to an outbreak of fungal meningitis among patients who received procedures under epidural anesthesia at 2 clinics (River Side Surgical Center and Clinica K-3)...
13.
Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management
Thompson 3rd G, Jenks J, Baddley J, Lewis 2nd J, Egger M, Schwartz I, et al.
Clin Microbiol Rev
. 2023 Jul;
36(3):e0001923.
PMID: 37439685
Fungal endocarditis accounts for 1% to 3% of all infective endocarditis cases, is associated with high morbidity and mortality (>70%), and presents numerous challenges during clinical care. spp. are the...
14.
OHalloran J, Ko E, Anstrom K, Kedar E, McCarthy M, Panettieri Jr R, et al.
JAMA
. 2023 Jul;
330(4):328-339.
PMID: 37428480
Importance: Immune dysregulation contributes to poorer outcomes in COVID-19. Objective: To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia. Design, Setting, And...
15.
Horwitz L, Thaweethai T, Brosnahan S, Cicek M, Fitzgerald M, Goldman J, et al.
PLoS One
. 2023 Jun;
18(6):e0286297.
PMID: 37352211
Importance: SARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms or other health effects after the acute phase of infection; termed post-acute sequelae of SARS-CoV-2 infection (PASC), or long...
16.
Ajetunmobi O, Chaturvedi A, Badali H, Vaccaro A, Najvar L, Wormley Jr F, et al.
APMIS
. 2023 Jun;
131(11):613-625.
PMID: 37337909
Candida spp. are opportunistic yeasts capable of forming biofilms, which contribute to resistance, increasing the urgency for new effective antifungal therapies. Repurposing existing drugs could significantly accelerate the development of...
17.
Thaweethai T, Jolley S, Karlson E, Levitan E, Levy B, McComsey G, et al.
JAMA
. 2023 Jun;
329(22):1934-1946.
PMID: 37278994
Importance: SARS-CoV-2 infection is associated with persistent, relapsing, or new symptoms or other health effects occurring after acute infection, termed postacute sequelae of SARS-CoV-2 infection (PASC), also known as long...
18.
Bonilla H, Peluso M, Rodgers K, Aberg J, Patterson T, Tamburro R, et al.
Front Immunol
. 2023 Mar;
14:1129459.
PMID: 36969241
Although most individuals recover from acute SARS-CoV-2 infection, a significant number continue to suffer from Post-Acute Sequelae of SARS-CoV-2 (PASC), including the unexplained symptoms that are frequently referred to as...
19.
Wiederhold N, Patterson T, Rebholz S, Brennan J, Patton T, Barrett J, et al.
Antimicrob Agents Chemother
. 2023 Jan;
67(2):e0147522.
PMID: 36645296
No abstract available.
20.
Ko E, Anstrom K, Panettieri R, Lachiewicz A, Maillo M, OHalloran J, et al.
medRxiv
. 2022 Oct;
PMID: 36203544
Background: We investigated whether abatacept, a selective costimulation modulator, provides additional benefit when added to standard-of-care for patients hospitalized with Covid-19. Methods: We conducted a master protocol to investigate immunomodulators...